WO2008003858A3 - Utilisation de dérivés d'imidazo[1, 2-a]pyridine-2-carboxamides en thérapeutique - Google Patents

Utilisation de dérivés d'imidazo[1, 2-a]pyridine-2-carboxamides en thérapeutique Download PDF

Info

Publication number
WO2008003858A3
WO2008003858A3 PCT/FR2007/001127 FR2007001127W WO2008003858A3 WO 2008003858 A3 WO2008003858 A3 WO 2008003858A3 FR 2007001127 W FR2007001127 W FR 2007001127W WO 2008003858 A3 WO2008003858 A3 WO 2008003858A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl group
carboxamides
imidazo
therapeutics
Prior art date
Application number
PCT/FR2007/001127
Other languages
English (en)
Other versions
WO2008003858A2 (fr
Inventor
Jean-Francois Peyronel
Original Assignee
Sanofi Aventis
Jean-Francois Peyronel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Jean-Francois Peyronel filed Critical Sanofi Aventis
Priority to EP07803835A priority Critical patent/EP2043643A2/fr
Priority to MX2008016550A priority patent/MX2008016550A/es
Priority to AU2007271010A priority patent/AU2007271010A1/en
Priority to CA002656363A priority patent/CA2656363A1/fr
Priority to BRPI0714317-6A2A priority patent/BRPI0714317A2/pt
Priority to JP2009517334A priority patent/JP2009541473A/ja
Publication of WO2008003858A2 publication Critical patent/WO2008003858A2/fr
Publication of WO2008003858A3 publication Critical patent/WO2008003858A3/fr
Priority to IL195949A priority patent/IL195949A0/en
Priority to US12/337,018 priority patent/US20090149494A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'utilisation de composés répondant à la formule (I), dans laquelle R1, R2, R3 et R4 sont hydrogène et X un groupe phényle éventuellement substitué par un ou plusieurs groupes choisis indépendamment les uns des autres parmi les atomes ou groupes suivants halogène, (C1-C6)alcoxy, (C1-C6)alkyle, cyclo(C1-C6)alkyle(C1-C6)alkyle, cyclo(C1-C6)alkyle(C1-C6)alcoxy, NRaRb; ou R2 est chlore et X est un para-fluoro-phényle; ou R3 est un méthyle et X est un groupe phényle non substitué; ou R1 est un méthyle et X est un groupe phényle non substitué, Ra et Rb sont indépendamment l'un de l'autre, hydrogène, (C1-C6)alkyle ou forment avec l'atome d'azote un cycle de 4 à 7 chaînons, à l'état de base ou de sel d'addition à un acide pour la préparation d'un médicament pour le traitement et la prévention des maladies dans lesquelles le récepteur NOT est impliqué.
PCT/FR2007/001127 2006-07-03 2007-07-03 Utilisation de dérivés d'imidazo[1, 2-a]pyridine-2-carboxamides en thérapeutique WO2008003858A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP07803835A EP2043643A2 (fr) 2006-07-03 2007-07-03 Utilisation de dérivés d'imidazo[1, 2-a]pyridine-2-carboxamides en thérapeutique
MX2008016550A MX2008016550A (es) 2006-07-03 2007-07-03 Utilizacion terapeutica de derivados de imidazo [1,2-a] piridin-2-carboxamidas.
AU2007271010A AU2007271010A1 (en) 2006-07-03 2007-07-03 Use of derivatives of imidazo[1, 2-a]pyridine-2-carboxamides in therapeutics
CA002656363A CA2656363A1 (fr) 2006-07-03 2007-07-03 Utilisation de derives d'imidazo[1, 2-a]pyridine-2-carboxamides en therapeutique
BRPI0714317-6A2A BRPI0714317A2 (pt) 2006-07-03 2007-07-03 Utilização de derivados de imidazo [ 1,2-alfa] piridina -21- carboxamidas em terapêutica.
JP2009517334A JP2009541473A (ja) 2006-07-03 2007-07-03 治療剤におけるイミダゾ［１，２−ａ］ピリジン−２−カルボキサミド誘導体の使用
IL195949A IL195949A0 (en) 2006-07-03 2008-12-15 Use of derivatives of imidazo[1,2-a]pyridine-2-carboxamides in therapeutics
US12/337,018 US20090149494A1 (en) 2006-07-03 2008-12-17 THERAPEUTIC USE OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606013A FR2903108B1 (fr) 2006-07-03 2006-07-03 Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
FR0606013 2006-07-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/337,018 Continuation US20090149494A1 (en) 2006-07-03 2008-12-17 THERAPEUTIC USE OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES

Publications (2)

Publication Number Publication Date
WO2008003858A2 WO2008003858A2 (fr) 2008-01-10
WO2008003858A3 true WO2008003858A3 (fr) 2008-04-17

Family

ID=37846294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001127 WO2008003858A2 (fr) 2006-07-03 2007-07-03 Utilisation de dérivés d'imidazo[1, 2-a]pyridine-2-carboxamides en thérapeutique

Country Status (13)

Country Link
US (1) US20090149494A1 (fr)
EP (1) EP2043643A2 (fr)
JP (1) JP2009541473A (fr)
KR (1) KR20090034861A (fr)
CN (1) CN101484168A (fr)
AU (1) AU2007271010A1 (fr)
BR (1) BRPI0714317A2 (fr)
CA (1) CA2656363A1 (fr)
FR (1) FR2903108B1 (fr)
IL (1) IL195949A0 (fr)
MX (1) MX2008016550A (fr)
RU (1) RU2009103302A (fr)
WO (1) WO2008003858A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2925900B1 (fr) * 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2925903B1 (fr) * 2008-01-02 2011-01-21 Sanofi Aventis DERIVES 6-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2925906B1 (fr) * 2008-01-02 2010-08-20 Sanofi Aventis COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
US20150329540A1 (en) * 2012-12-28 2015-11-19 Shin Nippon Biomedical Laboratories, Ltd. Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080911A2 (fr) * 2001-04-05 2002-10-17 Grünenthal GmbH Utilisation de composes imidazo[1,2-a]-pyridine-3-yl-amide- et imidazo[1,2-a]-pyridine-3-yl-amine substitues comme medicaments
WO2004072050A1 (fr) * 2003-02-14 2004-08-26 Novartis Ag Composes heterocycliques utiles en tant qu'activateurs de nurr-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2925901B1 (fr) * 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2925900B1 (fr) * 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080911A2 (fr) * 2001-04-05 2002-10-17 Grünenthal GmbH Utilisation de composes imidazo[1,2-a]-pyridine-3-yl-amide- et imidazo[1,2-a]-pyridine-3-yl-amine substitues comme medicaments
WO2004072050A1 (fr) * 2003-02-14 2004-08-26 Novartis Ag Composes heterocycliques utiles en tant qu'activateurs de nurr-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHMITT M ET AL: "IMIDAZO(1,2-B)PYRIDAZINES. XXIII SOME 5-DEAZA ANALOGUES. SYNTHESES OF SOME 2-ARYL-6-(CHLORO, METHOXY OR UNSUBSTITUTED)-3- (VARIOUSLY SUBSTITUTED)IMIDAZO(1,2-A)PYRIDINES AND THEIR AFFINITY FOR CENTRAL AND MITOCHONDRIAL BENZODIAZEPINE RECEPTORS", AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 50, no. 7, 1997, pages 719 - 725, XP001010372, ISSN: 0004-9425 *

Also Published As

Publication number Publication date
MX2008016550A (es) 2009-02-12
CN101484168A (zh) 2009-07-15
KR20090034861A (ko) 2009-04-08
WO2008003858A2 (fr) 2008-01-10
EP2043643A2 (fr) 2009-04-08
JP2009541473A (ja) 2009-11-26
FR2903108B1 (fr) 2008-08-29
BRPI0714317A2 (pt) 2014-06-24
IL195949A0 (en) 2009-09-01
FR2903108A1 (fr) 2008-01-04
CA2656363A1 (fr) 2008-01-10
AU2007271010A1 (en) 2008-01-10
US20090149494A1 (en) 2009-06-11
RU2009103302A (ru) 2010-08-10

Similar Documents

Publication Publication Date Title
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
JP2008530099A5 (fr)
WO2005092858A3 (fr) Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
TW200744587A (en) Azaindole derivatives exhibiting PGD2 receptor antagonism
WO2003024967A3 (fr) Composes chimiques
TW200621759A (en) Novel aminopyridine derivatives having aurora A selective inhibitory action
MX344669B (es) Agente antiplaquetas novedoso.
MY145603A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
WO2003064404A1 (fr) Hydrazides d'acide 2-furancarboxylique et compositions pharmaceutiques les contenant
MX2009011212A (es) Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
EP2597088A4 (fr) Antagoniste des récepteurs p2x4
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
WO2008003858A3 (fr) Utilisation de dérivés d'imidazo[1, 2-a]pyridine-2-carboxamides en thérapeutique
MX2010007351A (es) Derivados de imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapeutica.
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
WO2005095399A3 (fr) Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2006002802A8 (fr) Derives phenyle comprenant un groupe acetylene
MX2010007349A (es) Derivados de n-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas , su preparacion y su aplicacion terapeutica.
IL195837A0 (en) 4-amino-3-arylamino-6-arylpyrazolo[3,4-d]
WO2009028387A1 (fr) Agent thérapeutique pour le cancer avec une résistance à l'inhibiteur de la protéase
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780025224.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 195949

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2656363

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007271010

Country of ref document: AU

Ref document number: MX/A/2008/016550

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009517334

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007803835

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097000051

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 50/KOLNP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007271010

Country of ref document: AU

Date of ref document: 20070703

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009103302

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0714317

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090105